Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05143840 · ClinicalTrials.gov registry record · Phase 2
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
A Phase 2 study of Leukemia, Myeloid and Chronic Myeloid Leukemia, Chronic Phase, sponsored by Augusta University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 7
- Study locations
NCT05143840 is a Phase 2 study of Leukemia, Myeloid and Chronic Myeloid Leukemia, Chronic Phase that is actively recruiting participants, run by Augusta University. The registered enrollment target is 100 participants, below the 383-participant average among 8 other Leukemia, Myeloid trials with a reported enrollment target (74% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT05143840, a Phase 2 study of Leukemia, Myeloid and Chronic Myeloid Leukemia, Chronic Phase, is actively recruiting participants, sponsored by Augusta University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML-CP). The aim of this study is to evaluate the efficacy and safety of asciminib in newly diagnosed CML-CP. Patients will receive asciminib 80 mg orally once daily during the single asciminib phase. Response is determined by PCR (polymerase chain reaction) blood test during the study. Patients who have not achieved a response after 24 months (but no later than 36 months) of single agent asciminib will be offered the addition of a low dose tyrosine kinase inhibitor (low-TKI) namely dasatinib, imatinib, or nilotinib at the investigator's discretion. The following doses of the TKIs will be used: 1. Dasatinib 50 mg daily 2. Imatinib 300 mg daily 3. Nilotinib 300 mg daily Patients will discontinue study treatment if they experience disease progression, or unacceptable toxicity.
Conditions Studied
Interventions
- DRUG Single Agent Asciminib
- COMBINATION_PRODUCT Low TKI
- OTHER Elective Free Treatment
Study Locations (7)
Georgia
- Winship Cancer Institute Emory University - Atlanta
- Georgia Cancer Center at Augusta University - Augusta
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Memorial Sloan Kettering Cancer Center - New York
Michigan
- Karmanos Cancer Institute - Detroit
Utah
- Huntsman Cancer Institute - Salt Lake City
Wisconsin
- Froedtert Hospital & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-04-22 |
| Est. Completion | 2032-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05143840
The ClinicalTrials.gov registry entry for NCT05143840 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 383-participant average among 8 other Leukemia, Myeloid trials with a reported enrollment target (74% lower). The listed sponsor is Augusta University, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Leukemia, Myeloid appearing as the primary indexed condition, and to 3 interventions - of which Single Agent Asciminib is the first listed.
NCT05143840 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Georgia, New York, Michigan.
Frequently Asked Questions
What is clinical trial NCT05143840 about?
NCT05143840 is a clinical study titled "Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase". This study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML-CP). The aim of this study is to evaluate the efficacy and safety of asciminib in newly diagnosed CML-CP. ...
What is the current status of trial NCT05143840?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2022-04-22. Estimated completion is 2032-02.
What conditions does trial NCT05143840 study?
This clinical trial studies the following conditions: Leukemia, Myeloid, Chronic Myeloid Leukemia, Chronic Phase, Leukemia,Myeloid, Chronic, Adult CML.
What interventions are being tested in trial NCT05143840?
The interventions under investigation include: Single Agent Asciminib (DRUG), Low TKI (COMBINATION_PRODUCT), Elective Free Treatment (OTHER).
Who is sponsoring clinical trial NCT05143840?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05143840 being conducted?
This trial has 7 study locations across Georgia, Michigan, New York, Utah, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Myeloid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Allo HSCT Using RIC and PTCy for Hematological Diseases
RECRUITING · Phase 2
-
Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia
COMPLETED · Phase 2
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
RECRUITING · Phase 1
-
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.